DEXCOM (UK) DISTRIBUTION LIMITED

Company Registration Number:
10040080 (England and Wales)

Unaudited statutory accounts for the year ended 31 December 2024

Period of accounts

Start date: 1 January 2024

End date: 31 December 2024

DEXCOM (UK) DISTRIBUTION LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2024

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

DEXCOM (UK) DISTRIBUTION LIMITED

Directors' report period ended 31 December 2024

The directors present their report with the financial statements of the company for the period ended 31 December 2024

Principal activities of the company

The principal activity of the Company in the year under review was that of sales support and in the marketing and advertising of these products to markets outside of the United States of America.

Company policy on disabled employees

The Company gives full consideration to applications for employment from disabled persons where the candidates particular aptitudes and abilities are consistent with adequately meeting the requirements of the job. Opportunities are available to disabled employees for training, career development and promotion. Where existing employees become disabled, it is the Company's policy to provide continuing employment wherever practicable in the same or an alternative position and to provide appropriate training to achieve this aim.



Directors

The directors shown below have held office during the whole of the period from
1 January 2024 to 31 December 2024

Jereme Sylvain
Michael Jon Brown
Iskandar Moussa


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
26 September 2025

And signed on behalf of the board by:
Name: Iskandar Moussa
Status: Director

DEXCOM (UK) DISTRIBUTION LIMITED

Profit And Loss Account

for the Period Ended 31 December 2024

2024 2023


£

£
Turnover: 23,876 22,713
Gross profit(or loss): 23,876 22,713
Administrative expenses: ( 19,691 ) ( 18,922 )
Other operating income: 657 400
Operating profit(or loss): 4,842 4,191
Profit(or loss) before tax: 4,842 4,191
Tax: ( 1,243 ) ( 1,003 )
Profit(or loss) for the financial year: 3,599 3,188

DEXCOM (UK) DISTRIBUTION LIMITED

Balance sheet

As at 31 December 2024

Notes 2024 2023


£

£
Fixed assets
Tangible assets: 3 122 209
Total fixed assets: 122 209
Current assets
Debtors: 4 3,478 3,851
Cash at bank and in hand: 8,005 8,885
Total current assets: 11,483 12,736
Creditors: amounts falling due within one year: 5 ( 4,094 ) ( 4,034 )
Net current assets (liabilities): 7,389 8,702
Total assets less current liabilities: 7,511 8,911
Total net assets (liabilities): 7,511 8,911
Capital and reserves
Called up share capital: 1 1
Other reserves: 500
Profit and loss account: 7,510 8,410
Total Shareholders' funds: 7,511 8,911

The notes form part of these financial statements

DEXCOM (UK) DISTRIBUTION LIMITED

Balance sheet statements

For the year ending 31 December 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 26 September 2025
and signed on behalf of the board by:

Name: Iskandar Moussa
Status: Director

The notes form part of these financial statements

DEXCOM (UK) DISTRIBUTION LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Revenue is recognised under a full recharge and commissionaire agreement with Dexcom International Limited. Under the agreement, revenue is only recognised when the services are rendered and inputs can be measured reliably and it is probable that the Company will receive the consideration due under the agreement.

    Tangible fixed assets depreciation policy

    Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. Depreciation is provided on the following basis: Short term leasehold property - Shorter of the estimated useful life of the assets or the remaining lease term Fixtures and fittings - 5 years straight line Computer equipment - 3 years straight line The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in the Profit and Loss Account.

    Other accounting policies

    Going concern, foreign currency, Interest Income, Taxation, fixed asset investments, cash and cash equivalents, financial instruments, dividends, accounting judgements, share based payments, employee pension benefits

DEXCOM (UK) DISTRIBUTION LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

  • 2. Employees

    2024 2023
    Average number of employees during the period 94 93

DEXCOM (UK) DISTRIBUTION LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 January 2024 532 138 146 816
Additions
Disposals
Revaluations
Transfers
At 31 December 2024 532 138 146 816
Depreciation
At 1 January 2024 421 97 89 607
Charge for year 51 12 24 87
On disposals
Other adjustments
At 31 December 2024 472 109 113 694
Net book value
At 31 December 2024 60 29 33 122
At 31 December 2023 111 41 57 209

DEXCOM (UK) DISTRIBUTION LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

4. Debtors

2024 2023
£ £
Prepayments and accrued income 648 884
Other debtors 2,830 2,967
Total 3,478 3,851

DEXCOM (UK) DISTRIBUTION LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

5. Creditors: amounts falling due within one year note

2024 2023
£ £
Trade creditors 320 910
Taxation and social security 157 192
Accruals and deferred income 763 1,924
Other creditors 2,854 1,008
Total 4,094 4,034

DEXCOM (UK) DISTRIBUTION LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2024

6. Financial Commitments

At 31 December 2024 the Company had future minimum lease payments under non-cancellable operating leases as follows- 2024 2023 Not later than 1 year 43,303 69,665 Later than 1 year and not later than 5 years - 43,655 43,303 113,320